FT-7051 is a small molecule commercialized by Forma Therapeutics, with a leading Phase I program in Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of FT-7051’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for FT-7051 is expected to reach an annual total of $7 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

FT-7051 Overview

FT-7051 is under development for the treatment of metastatic castration-resistant prostate cancer. The drug candidate acts by targeting CREB (cAMP-responsive element-binding protein) binding protein (CBP)/E1A Binding Protein P300 (EP300). It is administered through oral route.

Forma Therapeutics Overview

Forma Therapeutics (Forma) is a biotech company. It develops technologies to identify the initial molecules that provide drug discovery program. It offers research in the areas of tumor metabolism, protein homeostasis, epigenetics, and protein-protein interactions. FORMA’s drug development process includes computational and medicinal chemistry, parallel synthesis, X-ray crystallography, and relevant biology studies. The company collaborates with biotechnology companies, pharmaceuticals and biomedicine companies and research institutes for its research and development activities. It operates offices in Watertown and Branford, the US. FORMA is headquartered in Watertown, Massachusetts, the US.

For a complete picture of FT-7051’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.